Cancer: Dendritic cell therapy in three separate laboratory studies prove positive effect on immune responses and values ​​might be important for metastatic cancer. Article posted in June 2005.

June 10, 2005: Source: PubMed, see the studies by-one

Although auto vaccination, the purest form of dendritic cell therapy has proven to be the first line for stage II colon cancer , little is known about dendritic cell therapy for metastatic colorectal cancer stage IIIB and IV. Here, three separate laboratory studies show that some form of dendritic cell therapy - dendritomas allogeneic (sorry do not dare to translate into Dutch afraid I say wrong) indeed strong immunological reactions, even against significant control studies and might be important for patients with metastatic colorectal cancer .. We will continue to search a little or even in vivo studies were done with dendritic cell therapy for metastatic cancer. Here the first three most recent laboratory studies.

Scand J Immunol. April 2005, 61 (4) :364-9.

Allogeneic anti-tumor immunity inducing dendritomas against colon cancer meta-static.

Xu F, Ye YJ, Cui ZR, Wang S.
Division of Surgical Oncology and Division of Gastrointestinal Surgery, Peking University People's Hospital, Beijing, PR China

Colon cancer (CC) is one of the most common malignancies in the Western world. Although surgical resection is the first choice worldwide, at this point an effective approach for the treatment or patient with metastasis and cancer recurrence post-operation not yet HAS leg found. The aim of this study was to Investigate the role of the allogeneic dendritic cell fusion or from dendritomas (DC) and meta-static CC cells in the activation of anti-tumor immunity against meta-static CC. Dendritomas were generated by fused allogeneic human peripheral blood DC with meta-static CC Cells Using 50% polyethylene glycol. The proliferation of the T cells and the toxicity of the cytotoxic T lymphocytes were observed after T cell pulsed with allogeneic dendritomas. The activated ratios of CD4 + T helper 1 and CD8 + cells were about Rc1 51.55 and 65.60% after T cells were mixed with fusions for 24 h, Which Higher Than Those of controls. The proliferation of T cells were significantly higher than Those of control after T cell pulsed with dendritomas (P <0.01). Significantly, the activated CD8 + T lymphocytes effectively lysed the CC cells. These results Demonstrate That dendritomas activate allogeneic T-cell responses against meta-static CC cells.

PMID: 15853920 [PubMed - indexed for MEDLINE]

World J Gastroenterol. 2004 April 15, 10 (8) :1162-6.

In vitro anti-tumor immune response induced by dendritic cells and fusion of colon cancer cells.

Xu F, Ye YJ, Wang S.
Tutor and Doctoral Students, Division of Surgical Oncology and Division of Gastrointestinal Surgery, People's Hospital, Peking University, Beijing 100044, China.

AIM: The prevention of recurrence of colon cancer (CC) after operation is very important for improvement of the CC or Prognosis Patients, Especially Those with micro-metastasis. The generation of dendritic cells fused Between cells (DCs) and tumor cells maybe an effective approach for tumor antigen presentation in immunotherapy. In this study, we fused human colon caner SW480 cells and human peripheral blood - derived DCs to induce an antitumor activity against human CC.

METHODS: CC SW480 cells and human peripheral blood - derived DCs were fused with 500 mL / L polyethylene glycol (PEG).

RESULTS: The specific T cell responses activated by fusion cells (FCS), were observed. About 100 mL / L to 160 mL / L of the PEG-treated non-adherent cells with fluorescences were Considered to be highly dendritomas Expressed That the key molecules for antigen presentation in our five cases. In vitro studies showed fusions effectively activated CD8 That (+) T lymphocytes to secrete interferon-gamma. The early apoptotic ratio of the colon cancer SW480 cells was higher than controls or That, All which was Affected by cytotoxic T lymphocytes (CTLs) stimulated by dendritomas.

CONCLUSION: The Data Indicating That fusion of tumor cells with DCs is an attractive strategy to induce tumor rejection.

PMID: 15069718 [PubMed - indexed for MEDLINE]

Zhonghua Yi Xue Za Zhi. 2004 May 2, 84 (9) :725-9.

[Dendritomas plays an important role in the activation of antitumor immune responses]

[Article in Chinese]

Xu F, Wang S, Ye YJ.
Department of Gastrointestinal Surgery, People's Hospital, Peking University, Beijing 100044, China.

OBJECTIVE: To Investigate the role of fusion or from dendritomas human dendritic cells (DCs) and colon cancer cells in the activation of MHC restricted anti-tumor reaction.

METHODS: Human dendritic cells and T cells were isolated from peripheral blood.Dendritomas were generated by fusing the human peripheral blood dendritic cells with human colon cancer cell line SW480 Using of the 50% polyethylene glycol (PEG). T cells were cultured. Dendritomas and DCs were added Into the culture respectively. The activation of T lymphocytes ratio was observed by MTT method. ELISA was Used to detect the content or interferon-gamma (IFN-gamma) in the supernatant.

RESULTS: The activation ratios of CD4 (+) Th1 and CD8 (+) cells were Rc1 57.45% and 77.86% respectively 24 hours after the T cells were mixed with dendritomas, significantly higher than Those Both of the controls. The proliferation of T cells mixed with dendritomas was significantly higher than That of the controls (P <0.01), The secretion of IFN-gamma the supernatant of the T cell culture 24 hours after mixing with the dendritomas was significantly higher than That of the control (P <0.01).

CONCLUSION: The strategy of dendritomas effectively activates the anti-tumor MHC I and MHC-II reactions and promoted the proliferation of T cells.

PMID: 15200907 [PubMed - indexed for MEDLINE]